Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update


      News provided by

      Reportlinker

      Jul 16, 2014, 05:05 ET

      Share this article

      Share this article


      NEW YORK, July 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

      OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

      http://www.reportlinker.com/p02238163/OpportunityAnalyzer-Cystic-Fibrosis---Opportunity-Analysis-and-Forecasts-to-2018---Event-Driven-Update.html

      OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

      Summary

      Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III clinical trial data for lumacaftor in combination with Kalydeco in patients with CF who have two copies of the F508del mutation. This novel combination therapy of CFTR modulators has the potential to treat the underlying cause of the disease for approximately 50% of all CF patients and drive rapid growth in the CF market.

      Highlights

      Key Questions Answered

      - What are the pressing unmet needs and remaining opportunities in the CF market?

      - What R&D strategies are drug developers pursuing in the CF therapeutics space?

      - What is the significance of CFTR modulators in the CF market?

      - What is the clinical and commercial positioning of key pipeline products in the CF market?

      - What are the innovative early-stage treatment approaches in the CF market?

      Key Findings

      - Rapid growth in the CF market is expected from 2012 to 2018.

      - Emerging market players are employing diverse R&D strategies to gain entry in the CF market.

      - A curative therapy is the most pressing unmet need in CF.

      - Significant opportunities exist for novel disease modifying drugs.

      Scope

      - Overview of CF, including epidemiology, etiology, pathophysiology, symptoms and current treatment options

      - Annualized CF therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018.

      - Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the CF therapeutics market.

      - Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including inhaled antibiotics, CFTR modulators and pancreatic enzyme products.

      - Analysis of the current and future market competition in the US and five major EU CF therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

      Reasons to buy

      - Identify the unmet needs and remaining opportunities in the CF therapeutics market.

      - Develop business strategies by understanding the trends shaping and driving the US and five major EU CF therapeutics market.

      - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

      - Assess the clinical and commercial viability of promising pipeline products.

      - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

      - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.

      - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

      - Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU CF therapeutics market in future.

      1 Table of Contents

      2 Introduction 14

      2.1 Catalyst 14

      2.2 Related Reports 15

      2.3 Upcoming Related Reports 15

      3 Disease Overview 16

      3.1 Etiology and Pathophysiology 16

      3.1.1 Etiology 16

      3.1.2 Pathophysiology 17

      3.1.3 Prognosis 19

      3.1.4 Quality of Life 20

      3.2 Symptoms 20

      4 Epidemiology 22

      4.1 Risk Factors and Co-morbidities 22

      4.2 Global and Historical Trends 23

      4.2.1 US 23

      4.2.2 France 24

      4.2.3 Germany 24

      4.2.4 Italy 25

      4.2.5 Spain 25

      4.2.6 UK 26

      4.3 Forecast Methodology 26

      4.3.1 Sources Used 26

      4.3.2 Forecast Assumptions and Methods 29

      4.3.3 Sources Not Used 32

      4.4 Epidemiology Forecast 32

      4.4.1 Total Prevalent Cases of Cystic Fibrosis 32

      4.4.2 Total Prevalent Cases of Cystic Fibrosis Segmented by Age 34

      4.4.3 Total Prevalent Cases of Cystic Fibrosis Segmented by Sex 35

      4.4.4 Total Prevalent Cases of Cystic Fibrosis by Mutation Type 35

      4.5 Discussion 37

      4.5.1 Conclusion on Epidemiology Trends 37

      4.5.2 Limitations of the Analysis 37

      4.5.3 Strengths of the Analysis 38

      5 Current Treatment Options 39

      5.1 Overview 39

      5.2 Product Profiles - Major Brands, Inhaled Antibiotics 41

      5.2.1 TOBI (tobramycin) 41

      5.2.2 TOBI Podhaler (tobramycin inhalation powder) 44

      5.2.3 Bramitob (tobramycin) 50

      5.2.4 Colistimethate Sodium (nebulized; numerous generic names) 53

      5.2.5 Colobreathe (colistimethate sodium dry powder) 56

      5.2.6 Cayston (aztreonam) 59

      5.3 Product Profiles - Major Brands, Mucolytics 63

      5.3.1 Pulmozyme (dornase alfa) 63

      5.3.2 Bronchitol (mannitol) 66

      5.4 Product Profiles - Major Brands, CFTR Modulators 71

      5.4.1 Kalydeco (ivacaftor, VX-770) 71

      5.5 Product Profiles - Major Brands, Other Therapies 77

      5.5.1 Pancreatic Enzyme Replacement Therapies (PERTs) 77

      6 Unmet Needs Assessment and Oppportunity Analysis 80

      6.1 Overview 80

      6.2 Unmet Needs Analysis 81

      6.2.1 The Development of Curative Therapies 81

      6.2.2 Improving Treatment of CF-related Lung Infections 82

      6.2.3 Improving Airway Clearance with Mucolytic Agents 83

      6.2.4 Improving Treatment Compliance 84

      6.2.5 The Development of Safe Anti-inflammatory Therapies 85

      6.3 Opportunity Analysis 86

      6.3.1 Therapies that Target CFTR Protein Function 86

      6.3.2 New Classes and Formulations of Inhaled Antibiotics 86

      6.3.3 Novel Mucolytic Agents 87

      6.3.4 Novel Anti-inflammatory Agents 88

      7 R&D Strategies 90

      7.1 Overview 90

      7.1.1 Reformulation Strategies 90

      7.1.2 Personalized Treatment Approach 90

      7.1.3 Diverse Proof-of-Concept Research 91

      7.1.4 Licensing and Alliances 92

      7.2 Clinical Trial Design 92

      8 Pipeline Assessment 95

      8.1 Overview 95

      8.2 Promising Drugs in Clinical Development 95

      8.3 Promising Drugs in Clinical Development, Inhaled Antibiotics 96

      8.3.1 Arikayce (amikacin) 96

      8.4 Promising Drugs in Clinical Development, CFTR Modulators 101

      8.4.1 Lumacaftor (VX-809)/Kalydeco (VX-770) 101

      8.4.2 Ataluren (PTC124) 105

      8.5 Innovative Early-Stage Approaches 109

      9 Pipeline Valuation Analysis 113

      9.1 Clinical Benchmark of Key Pipeline Drugs 113

      9.2 Commercial Benchmark of Key Pipeline Drugs 114

      9.3 Competitive Assessment 116

      9.4 Top-Line Six-Year Forecast 117

      9.4.1 US 119

      9.4.2 5EU 120

      10 Appendix 122

      10.1 Bibliography 122

      10.2 Abbreviations 137

      10.3 Methodology 140

      10.4 Forecasting Methodology 140

      10.4.1 Diagnosed CF Patients 140

      10.4.2 Percent Drug-treated Patients 140

      10.4.3 Drugs Included in Each Therapeutic Class 141

      10.4.4 Launch and Patent Expiry Dates 141

      10.4.5 General Pricing Assumptions 142

      10.4.6 Drug Assumptions 142

      10.4.7 Generic Erosion 144

      10.4.8 Pricing of Pipeline Agents 144

      10.5 Physicians and Specialists Included in this Study 145

      10.6 About the Authors 146

      10.6.1 Analyst 146

      10.6.2 Reviewer 146

      10.6.3 Epidemiologist 147

      10.6.4 Global Head of Healthcare 147

      10.7 About GlobalData 148

      10.8 Disclaimer 148

      1.1 List of Tables

      Table 1: Classes of the CFTR Gene Mutations in Cystic Fibrosis 17

      Table 2: Symptoms of Cystic Fibrosis 21

      Table 3: Six Major Markets, Sources of Cystic Fibrosis Prevalence Data 27

      Table 4: Six Major Markets, Sources of Cystic Fibrosis-Causing Mutation Data 27

      Table 5: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, Men and Women, Selected Years, 2012-2022 33

      Table 6: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, By Sex, 2012, N (%) 35

      Table 7: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0-35 Years, Men and Women, 2012 36

      Table 8: Leading Treatments for Cystic Fibrosis, 2014 40

      Table 9: Product Profile - TOBI 42

      Table 10: Product Profile - TOBI Podhaler 46

      Table 11: Product Profile - Bramitob 51

      Table 12: Product Profile - Colistimethate Sodium 54

      Table 13: Product Profile - Colobreathe 57

      Table 14: Product Profile - Cayston 60

      Table 15: Product Profile - Pulmozyme 64

      Table 16: Product Profile - Bronchitol 67

      Table 17: Product Profile - Kalydeco 73

      Table 18: Overall Unmet Needs - Current Level of Attainment 81

      Table 19: Cystic Fibrosis - Late-Stage Pipeline, 2014 95

      Table 20: Product Profile - Arikayce 97

      Table 21: Product Profile - Lumacaftor/Kalydeco 102

      Table 22: Product Profile - Ataluren 106

      Table 23: Early-Stage Pipeline Products in Cystic Fibrosis, 2014 112

      Table 24: Clinical Benchmark of Key Pipeline Drugs - Inhaled Antibiotics 113

      Table 25: Clinical Benchmark of Key Pipeline Drugs - CFTR Modulators 114

      Table 26: Commercial Benchmark of Key Pipeline Drugs - Inhaled Antibiotics 115

      Table 27: Commercial Benchmark of Key Pipeline Drugs - CFTR Modulators 115

      Table 28: Top-Line Sales Forecasts ($m) for Cystic Fibrosis, 2012-2018 118

      Table 29: Key Events Impacting Sales for Cystic Fibrosis, 2012-2018 121

      Table 30: Cystic Fibrosis Market - Drivers and Barriers, 2012-2018 121

      Table 31: Key Launch Dates 141

      Table 32: Key Patent Expiries 141

      List of Figures

      Figure 1: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, Men and Women, Selected Years, 2012-2022 33

      Figure 2: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, By Age, Men and Women, 2012 34

      Figure 3: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0-35 Years, Men and Women, 2012 36

      Figure 4: Competitive Assessment of Late-Stage Pipeline Inhaled Antibiotics in Cystic Fibrosis, 2012-2018 116

      Figure 5: Competitive Assessment of Late-Stage Pipeline CFTR Modulators in Cystic Fibrosis, 2012-2018 117

      Figure 6: Sales for Cystic Fibrosis by Region, 2012-2018 118

      To order this report: OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

      http://www.reportlinker.com/p02238163/OpportunityAnalyzer-Cystic-Fibrosis---Opportunity-Analysis-and-Forecasts-to-2018---Event-Driven-Update.html

      __________________________

      Contact Clare: [email protected]

      US: (339)-368-6001

      Intl: +1 339-368-6001

      SOURCE Reportlinker

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.